Pharmaceutical, Biotechnology & Life Sciences Marketing, AI & Growth Consulting
A molecule can be elegant, a platform can be revolutionary, a dataset can be enormous—and the company can still fail to explain why any of it matters to the scientist, clinician, partner, investor, payer, regulator or patient standing on the other side of the decision.
I help pharmaceutical, biotech and life-science organizations connect scientific truth to commercial reality: positioning, go-to-market strategy, technical storytelling, laboratory authority, AI search, SEO, websites, paid acquisition, account-based marketing, medical and scientific communications, partnerships, investor visibility and growth.
For companies whose science is too important to flatten into “innovative solutions.” Senior strategy, technical depth and direct involvement from discovery-stage stories through commercial markets.
Life sciences growth is the art of making several sophisticated audiences understand the same company for different reasons.
A scientist may care about mechanism and reproducibility. A business-development team may care about platform leverage. A regulator cares about evidence and risk. A hospital may care about workflow and economics. An investor may care about probability-adjusted value. A patient wants to know what the treatment means for life.
That is why I do not reduce life-science marketing to a campaign calendar. I want to understand the product, platform, pipeline, evidence, intellectual property context, manufacturing reality, regulatory stage, competitive landscape, buyer, adoption barrier and commercial objective.
Sometimes the job is to make an early biotechnology company legible enough for partners and investors. Sometimes it is to help a mature pharmaceutical company explain a therapeutic area without crossing promotional lines. Sometimes it is a CDMO trying to win programs, a diagnostic company trying to reach health systems, a scientific-software company trying to enter enterprise labs or a device company sitting directly beside a therapy.
From molecule to market—and all the people who have to believe the evidence along the way.
A biotech company can have a messaging problem that is actually a science-stage problem.
A discovery-stage platform can sound weak because nobody has decided whether the company is selling a mechanism, a therapeutic pipeline, a research capability or a partnering opportunity. A clinical-stage biotech can look confusing because the corporate story and the lead asset tell two different stories. A CDMO can generate plenty of traffic while failing to prove the technical capabilities that procurement and process-development teams actually care about.
Pharma adds another layer. The audience may range from HCPs and patients to payers, health systems, advocacy communities and regulators. Commercial communication must live beside medical affairs, labeling, pharmacovigilance, market access and legal review. “Make it punchier” is not a useful strategy when the sentence is describing a clinical outcome, an investigational asset or a product with material risk information.
I want to know what commercial event the communication has to support: a financing, licensing conversation, IND milestone, clinical-trial enrollment effort, partnership, launch, formulary discussion, account win, scientific conference, talent search or durable category position.
The pipeline keeps changing because biology keeps refusing to become simple.
FDA's Center for Drug Evaluation and Research approved 46 novel drugs in 2025 alone, while the current FDA list of licensed cellular and gene-therapy products continues to expand across oncology, rare disease, hematology, ophthalmology and other areas.
Sources: FDA 2025 Novel Drug Approvals, FDA Approved Cellular and Gene Therapy Products, and FDA CASGEVY product information.
The commercial lesson is not that every life-science company needs to chase the newest modality. It is that the market now contains small molecules, monoclonal antibodies, bispecifics, antibody-drug conjugates, radiopharmaceuticals, RNA therapeutics, cell therapies, gene therapies, gene editing, digital measurement, companion diagnostics and device-enabled delivery systems—all with different evidence, manufacturing, adoption and communication burdens.
“Biotech company” can describe a pre-revenue platform, a marketed therapy or a manufacturer selling capacity.
The story should mature as the evidence matures.
Early science communication can be ambitious while remaining explicit about what is preclinical or investigational. As clinical evidence accumulates, the narrative can become more specific about populations, endpoints and observed results. After approval, the commercial organization inherits a different obligation: the product story has to remain consistent with the approved labeling and applicable promotional rules.
A drug launch is not a consumer-product launch with more footnotes.
HCP strategy
Physicians, advanced-practice clinicians, pharmacists and other HCPs may need disease-state education, clinical data, dosing and administration context, patient-selection information, safety information and a clear reason to consider a product inside an existing treatment pathway.
Patient communication
Patients need understandable language about the condition, treatment, practical experience and risks without turning hope into certainty. Consumer communication should recognize that treatment choice still belongs inside a clinician-patient relationship.
Health-system adoption
Hospitals and large groups may care about formulary, pathways, administration burden, infusion or monitoring needs, site-of-care economics, pharmacy operations and the practical consequences of adding a therapy.
Lifecycle management
New indications, formulations, delivery systems, combinations and line extensions can change the commercial story over time. Each change needs accurate labeling and evidence context.
Generics & biosimilars
Competition may shift from novelty toward comparability, access, contracting, interchangeability questions, supply reliability and clinician confidence. The marketing problem changes when the category already exists.
Rare disease
Small populations can require disproportionate depth: specialist mapping, diagnostic pathways, patient advocacy, genetic testing, centers of excellence and careful expectations around eligibility and access.
FDA's Office of Prescription Drug Promotion states its mission plainly: prescription-drug promotion should be truthful, balanced and accurately communicated. That principle has to survive websites, sales materials, HCP campaigns, social media, video and any clever new format marketing discovers next.
Reference: FDA Office of Prescription Drug Promotion. Paper Boat Media also maintains a focused Pharmaceutical Marketing presence for narrower pharma intent.
The molecule does not enter a market. It enters a disease, a care pathway and a community that already has habits.
Oncology, rare disease, obesity, vaccines and neuroscience may all be “pharma,” but the patient-finding problem, specialist network, evidence expectations, site-of-care reality and commercial model can be radically different.
Oncology & precision oncology
Oncology can depend on histology, stage, line of therapy, biomarkers, molecular testing, companion diagnostics, infusion infrastructure, tumor boards, guidelines and specialist centers. A therapy's commercial path may be inseparable from whether the right patient gets tested and reaches the right oncologist. ADCs, bispecifics, cell therapies, targeted therapies and radiopharmaceuticals each create different education and operational burdens.
Rare & genetic disease
The challenge may begin years before treatment with diagnosis. Genetic confirmation, newborn screening, specialist awareness, patient advocacy, natural-history understanding and centers of excellence can matter more than mass media. A small population does not make the strategy small; it often makes every missed referral more consequential.
Immunology & inflammation
Autoimmune and inflammatory markets can involve chronic treatment, specialist competition, biologics, small molecules, step therapy, long-term safety and crowded classes. Differentiation may depend on efficacy, route, convenience, onset, durability, safety, patient selection and access rather than a brand story alone.
Neuroscience & psychiatry
CNS development carries difficult endpoints, heterogeneous disease biology, caregiver burden and enormous unmet need. Neurology may involve infusion, specialty centers or biomarkers; psychiatry adds stigma, access and behavioral-health systems. The communication has to respect uncertainty without making the disease feel abstract.
Metabolic disease & obesity
GLP-1-class drugs changed public awareness of obesity medicine and created an unusually visible intersection of chronic disease, prescribing, payer coverage, supply, telehealth, compounded-product confusion and consumer demand. Metabolic strategy should connect evidence, indication, access, long-term care and realistic treatment pathways rather than ride a cultural trend.
Cardiovascular & renal
Cardiometabolic products can involve primary care, cardiology, nephrology, endocrinology, hospital systems and very large eligible populations. Prevention, risk reduction, adherence, guideline integration and payer impact may matter as much as specialist launch strategy.
Infectious disease & vaccines
Vaccines and anti-infectives live inside public health, surveillance, seasonality, provider recommendation, procurement, distribution and sometimes rapidly changing epidemiology. Vaccine communication also operates in a high-misinformation environment where trust, transparency and source quality matter enormously.
Ophthalmology & retinal disease
Eye-care therapeutics can involve retinal specialists, injection burden, imaging, genetics, surgery and highly specialized delivery. Gene therapy and durable delivery approaches can change both clinical and economic assumptions about chronic treatment.
Reproductive & women's health
Fertility, contraception, menopause, maternal medicine and reproductive therapeutics involve deeply personal decisions, changing policy environments and a mix of specialists, patients, employers and payers. Scientific precision has to coexist with unusually careful human communication.
Respiratory & allergy
Asthma, COPD, allergy and rare pulmonary disease can involve inhaled delivery, biologics, pulmonary testing, specialty physicians and adherence. Device technique may become part of the drug's real-world effectiveness.
Dermatology
Dermatology combines visible disease, quality-of-life impact, biologics, immunology, topical therapy and consumer awareness. Patient imagery can educate powerfully while still requiring dignity, consent and realistic expectations.
Pediatrics
Pediatric development changes dosing, formulation, consent, caregiver communication, endpoints and long-term considerations. In rare disease and gene therapy, the family may be making an extraordinarily high-stakes decision under time pressure.
Platform biotech has to explain two things at once: why the technology works and why it should produce a company rather than a paper.
A platform story can be harder than a single-asset story because the company wants investors and partners to see repeatability, leverage and optionality without implying that one proof point validates every future program. The corporate narrative has to connect mechanism to pipeline logic.
A synthetic-biology company might be selling engineered organisms, enzymes or manufacturing capability. A delivery platform may need to prove tissue targeting, payload compatibility and manufacturability. A discovery platform may depend on proprietary data, automation or AI. A gene-editing company may have to explain specificity, delivery, durability, off-target considerations and why its editing approach fits a disease.
I want the science team to recognize itself in the story and the business audience to understand why the science creates strategic value. If either group feels patronized, the message is wrong.
CRISPR crossed from headline to approved medicine. The frontier did not stop moving.
The commercial opportunity is enormous precisely because the science is difficult. A serious company should make novelty easier to understand without pretending novelty has already eliminated biological risk.
CRISPR/Cas gene editing
CRISPR systems can be directed to specific genomic locations to edit DNA. CASGEVY demonstrated that genome editing can move through manufacturing, clinical development and FDA approval. The current product uses ex vivo CRISPR/Cas9 editing of a patient's own hematopoietic stem cells rather than editing a person's tissues directly inside the body.
Base editing
Base editors are designed to change particular DNA bases without creating the same double-strand break used in classic nuclease editing. The commercial story involves editing window, targeting, delivery, bystander edits, safety and whether the approach creates a meaningful therapeutic advantage.
Prime editing
Prime editing is another programmable approach designed to make targeted sequence changes. It is scientifically compelling, but clinical maturity and delivery differ by program. Marketing should describe development stage explicitly rather than borrowing the credibility of approved CRISPR therapies.
RNA therapeutics
mRNA, siRNA, antisense oligonucleotides and other RNA-based approaches create different opportunities for transient expression, gene silencing, splicing or protein production. Delivery and tissue targeting can be as commercially important as sequence design.
Targeted protein degradation
PROTACs and related degrader approaches aim to recruit cellular machinery to remove disease-relevant proteins rather than merely inhibit them. The market story lives in target biology, selectivity, pharmacology and clinical evidence—not the cleverness of the molecular diagram.
Radiopharmaceuticals
Targeted radiotherapies connect ligand biology, isotope selection, dosimetry, manufacturing, handling, site readiness and oncology pathways. The commercial system therefore includes nuclear medicine and logistics as well as drug development.
Bispecifics & multispecifics
Antibodies engineered to engage more than one target can create powerful therapeutic mechanisms and complicated safety, administration and patient-selection stories. The communication should make the mechanism useful rather than merely impressive.
Antibody-drug conjugates
ADCs combine targeting antibodies with payloads and linkers. Target expression, internalization, payload behavior, toxicity and resistance can all become part of the commercial and medical narrative.
Organoids & advanced models
Organoids, organ-on-chip systems and advanced human-relevant models can influence discovery, toxicology and translational research. The business model may be a research tool, service, platform partnership or internal development engine rather than a therapy itself.
Synthetic biology
Engineered cells, microbes, circuits and biological manufacturing platforms can create medicines, materials, diagnostics and industrial products. The same core science can lead to completely different buyers and regulatory pathways.
Spatial & single-cell biology
Single-cell and spatial methods can reveal heterogeneity and tissue context hidden by bulk measurements. They can support discovery, biomarker strategy, diagnostics and research tools—and generate enough data to make interpretation the limiting reagent.
Neurotechnology & biointerfaces
Brain-computer interfaces, neural stimulation, bioelectronic medicine and sensory technologies increasingly connect biology with devices, software and rehabilitation. That intersection requires both scientific and engineering fluency.
Current example: FDA's July 2026 CASGEVY approval information describes the therapy's autologous stem cells as edited with CRISPR/Cas9 and expanded the labeled patient population to age 2 and older for specified SCD and TDT indications. FDA July 1, 2026 release. Related PBM work: Frontier Science & Deep Technology.
For advanced therapies, manufacturing and care delivery become part of the product story.
Autologous cell therapy
Patient-specific collection, manufacturing, release, logistics, conditioning and treatment-center readiness can create a therapy journey measured in weeks rather than a prescription filled at a pharmacy. Commercial communication has to explain a system.
Allogeneic cell therapy
Off-the-shelf approaches may change manufacturing and access economics but introduce their own biology, persistence, compatibility and process-control questions. Platform claims should track actual clinical evidence.
CAR-T / engineered immune cells
Cellular immunotherapies can require specialized centers, patient identification, referral pathways, bridging therapy, toxicity management, manufacturing slots and complex coordination. Treatment-center operations are part of adoption.
In vivo gene therapy
AAV and other delivery systems can bring genetic material directly into patients. Vector biology, tropism, dose, immunity, durability, manufacturing and safety belong inside the story when relevant.
Ex vivo gene editing
Cells can be collected, edited outside the body, characterized and returned to the patient. That creates a hybrid of molecular science, cell manufacturing, laboratory analytics and transplant-like clinical logistics.
Rare-disease ecosystems
Many advanced therapies serve small populations. Diagnosis, genetic confirmation, specialist centers, advocacy organizations and family education can determine whether an eligible patient ever reaches the treatment pathway.
FDA's current licensed cellular and gene-therapy list includes CAR-T products, gene therapies, engineered tissues and other advanced products, reflecting how broad this category has become. I would never describe a platform as “gene therapy” merely because DNA appears somewhere in the slide deck; regulatory product type and mechanism matter.
The laboratory is where a life-science story becomes measurable.
Drug discovery depends on assays. Biomarker programs depend on analytical validity. Cell and gene therapies depend on identity, potency, purity and process controls. Clinical trials depend on central labs, bioanalytics, pathology, genomics and sample logistics. Manufacturing depends on QC. Precision medicine often depends on companion diagnostics. The laboratory is not a support character. It is part of the evidence engine.
That is also an area where Paper Boat Media already has unusually strong organic visibility. My Laboratory Marketing Agency work addresses clinical and diagnostic laboratories, analytical labs, molecular testing, pathology, laboratory equipment, LIMS/LIS/ELN, automation, scientific software, instrumentation and technical B2B demand.
The life-science connection is natural: a biotech company may need an assay partner, central lab, sequencing provider, bioanalytical CRO, histopathology service, instrument platform or diagnostic strategy long before commercialization. A laboratory may in turn need biotech, pharma and research organizations as customers.
Not every life-science company makes a therapy. Some make the therapy possible.
Research tools and enabling technologies sell into scientists, laboratories, biopharma R&D, core facilities, translational groups, manufacturing teams and universities. Their commercial proof is often application-specific.
Sequencing & genomics tools
Sequencers, library preparation, panels, informatics and genomic workflows compete through performance, throughput, cost, sample requirements, applications and ecosystem compatibility. The buyer wants to know what research question becomes possible or easier.
Single-cell & spatial platforms
Single-cell and spatial technologies create rich biological resolution and complex workflows. Application notes, datasets, methods, publications and credible scientist-to-scientist education can be more persuasive than broad brand advertising.
Flow cytometry & cell analysis
Instruments, reagents, panels and software may serve research, clinical and advanced-therapy workflows. Buyers care about sensitivity, complexity, throughput, standardization, service and whether the platform fits existing laboratory practice.
Mass spectrometry & analytical instruments
Mass spectrometry, chromatography, spectroscopy and related systems sell through method fit, performance, applications, service, installed base and total workflow. Commercial content should respect the sophistication of analytical buyers.
Automation & laboratory robotics
Automation can address throughput, reproducibility, labor, traceability and standardization. The buyer may be a research lab, clinical lab, bioprocessing team or high-throughput discovery organization, each with different integration constraints.
Organoids, cell models & reagents
Cell lines, organoids, culture systems, reagents and advanced models can become enabling platforms for discovery and translational work. Reproducibility, characterization, biological relevance and workflow fit are central to trust.
LIMS, ELN & scientific software
Scientific software must sell to both the person doing the work and the people responsible for data integrity, IT, security, compliance and enterprise integration. “Digital transformation” means very little if the bench scientist hates using the system.
Bioprocessing technologies
Bioreactors, single-use systems, filtration, purification, sensors, process analytics and fill-finish technologies can influence yield, control, scale and manufacturing flexibility. Technical content should connect equipment capability to process consequences.
Scientific data & cloud infrastructure
Life-science data platforms can combine storage, analysis, collaboration, machine learning and workflow orchestration. The commercial buyer may include scientists, computational teams, IT, security and executive leadership at the same account.
The strongest overlap with laboratory marketing is deliberate. Equipment, automation, LIMS, analytical methods and scientific software already sit inside my laboratory marketing work because those buyers often begin with a method or workflow problem rather than the name of a vendor.
Sometimes the therapy is a molecule. Sometimes the therapy cannot work without the thing that delivers, measures or guides it.
Medical devices deserve substantive attention inside life sciences because drugs, diagnostics, delivery systems and hardware increasingly meet in the same patient pathway.
Drug-delivery devices
Autoinjectors, pens, pumps, inhalers, infusion systems and other delivery technologies can change adherence, usability, dosing and commercial differentiation. Human factors and the constituent parts of combination products become part of development.
Companion diagnostics
A therapeutic may depend on a test that identifies the right biomarker, genotype or tumor feature. That links drug development to laboratory workflow, pathologists, oncologists, test availability and device regulation.
IVDs & molecular diagnostics
In vitro diagnostics can sit beside therapeutics or exist as independent products. The buyer may include laboratories, health systems, physicians, public health, payers or consumers depending on the intended use and setting.
Surgical & interventional technologies
Catheters, implants, robotic systems, navigation, ablation and image-guided technologies may change a clinical pathway even when no drug is involved. Adoption then depends on physicians, hospitals, capital budgets, training and procedure economics.
Software & AI-enabled devices
Clinical software can be a device depending on intended use. AI adds lifecycle, validation, data and update questions that differ from ordinary SaaS marketing.
Regulatory pathway matters
FDA device pathways include 510(k), De Novo and PMA among others. A 510(k) clearance is not the same as PMA approval, and “registered with FDA” is not a synonym for an approved product claim.
Reference: FDA How to Study and Market Your Device. Device-led products require their own technical, regulatory, reimbursement and procurement strategy; the life-science connection here focuses on the places devices and therapeutics genuinely intersect.
The treatment can only be precise if the measurement is good enough to make the distinction.
Biomarkers
Predictive, prognostic, pharmacodynamic and other biomarkers can influence development and treatment decisions. The label and evidence determine what a marker can legitimately claim to do.
Companion diagnostics
Therapy and test may be commercially linked. Adoption requires enough testing capacity, specimen workflow and clinician understanding for eligible patients to be identified.
Liquid biopsy
Circulating tumor DNA and other analytes can support oncology applications, but sensitivity, specificity, disease stage, intended use and evidence matter more than the phrase “simple blood test.”
Multi-omics
Genomics, transcriptomics, proteomics, metabolomics and spatial data can improve biological resolution while multiplying analytical complexity. The commercial product is often interpretation as much as measurement.
The molecule is not commercial until somebody can make it, test it, release it and keep making it.
CDMO / CMO
Contract development and manufacturing organizations sell technical capability, quality, capacity, regulatory experience, scale-up, tech transfer, timeline confidence and relationship quality. A qualified lead may be one program worth years of revenue.
API & specialty chemistry
Small-molecule API manufacturing can involve route development, process chemistry, impurity control, analytical methods, containment, scale, supply assurance and documentation. Technical content should help a development team self-qualify the supplier.
Biologics manufacturing
Cell culture, upstream/downstream processing, purification, fill-finish, cold chain and analytical characterization become part of buyer confidence. Capacity claims should be specific enough to be useful.
Cell & gene manufacturing
Viral vectors, plasmids, cell processing, gene editing, chain of identity, chain of custody, cryopreservation and release testing create specialized commercialization and operational stories.
CRO & clinical services
CROs compete on therapeutic expertise, operations, sites, data, biostatistics, regulatory capability, speed and execution. One generic “end-to-end” page rarely proves why a sponsor should trust a particular program.
Supply chain & quality
Cold chain, raw materials, single-use systems, fill-finish, packaging, serialization and distribution can become strategic constraints. Marketing is strongest when it shows operational reliability instead of merely saying “quality.”
Life-science manufacturing also intersects with my broader manufacturing, industrial and supply-chain strategy, where technical buying, qualification and long-cycle enterprise sales operate differently from patient-facing healthcare.
A trial needs participants, investigators and sites. It also needs communication that does not accidentally market an investigational product as proven treatment.
Clinical-development communication can include corporate pipeline pages, trial finders, investigator outreach, site materials, patient-friendly study explanations, advocacy relationships, recruitment campaigns and scientific-congress activity. Each audience needs enough information to make the next appropriate decision without turning recruitment into efficacy promotion.
Rare disease and oncology can require especially thoughtful trial ecosystems because eligibility may depend on biomarkers, prior therapy, geography or specialized centers. Cell and gene therapy trials may add manufacturing windows, collection, conditioning and treatment-center capability.
I can help make those pathways understandable and discoverable. Protocol design, eligibility, informed consent, clinical conduct and regulatory decisions remain with sponsors, investigators, IRBs and qualified clinical/regulatory professionals.
Commercial communication and scientific exchange are neighbors. They should not be mistaken for twins.
Medical affairs may support scientific exchange, publications, congresses, field medical teams, evidence generation and HCP education. Commercial teams have different objectives and promotional constraints.
Scientific congresses
Abstracts, posters, oral presentations, booth strategy, meeting content, digital amplification and post-congress education can build category authority while respecting the status of the data.
Publications & evidence
Peer-reviewed evidence, study design, endpoints, limitations and reproducibility deserve more attention than a cherry-picked headline. Scientific credibility compounds.
KOL & HCP education
Experts can help a field understand disease biology, new evidence and clinical context. Relationships, disclosures and role boundaries need to remain clear.
FDA issued final guidance in January 2025 addressing certain firm communications of scientific information to HCPs about unapproved uses of approved or cleared medical products. That is exactly the sort of area where the legal, regulatory, medical and communications teams need to stay aligned rather than assume that “scientific” automatically means unrestricted.
Reference: FDA guidance on scientific information regarding unapproved uses.
Approval answers one question. Adoption starts several more.
A therapy can be clinically important and commercially difficult if reimbursement, testing, administration, distribution, site readiness or patient identification do not work.
Payer value
Plans and formulary decision-makers may evaluate clinical evidence, comparators, population, budget impact, utilization management and total treatment pathway. The value story has to be specific to the decision-maker.
Site of care
Infused, administered or procedure-linked therapies can change staffing, scheduling, facilities, pharmacy workflow, monitoring and economics. Health-system adoption is partly operational.
Diagnostic access
A precision therapy cannot reach the right patient if biomarker testing is unavailable, slow or poorly understood. Test adoption can therefore become part of therapy adoption.
Patient services
Coverage support, onboarding, education, logistics and adherence programs can influence whether an approved therapy is practically accessible. Communication should remain clear about the program's role.
Centers of excellence
Rare disease, gene therapy and complex specialty products may depend on a small number of experienced centers. Referral mapping and professional education become strategic.
Evidence after launch
Real-world evidence, registries, safety monitoring and additional studies can reshape clinical understanding and commercial position over time.
AI can help find patterns. Biology still gets a vote.
AI now touches target identification, molecule design, protein modeling, imaging, omics, trial operations, manufacturing, pharmacovigilance, medical writing, literature analysis and regulatory workflows.
Discovery AI
Machine learning can prioritize targets, molecules or hypotheses and help navigate enormous chemical or biological spaces. The commercial claim should distinguish computational prediction from experimentally or clinically validated performance.
Clinical & biomarker AI
Models may support patient stratification, imaging, endpoint analysis or biomarker discovery. Data provenance, bias, context of use and validation become part of credibility.
Manufacturing AI
Process monitoring, predictive maintenance, quality analytics and advanced controls can influence biomanufacturing. Regulated use requires more than showing that an algorithm improves a dashboard.
Regulatory AI
FDA's January 2025 draft guidance proposes a risk-based credibility assessment framework for AI models used to generate information supporting regulatory decisions about drug and biological product safety, effectiveness or quality.
Knowledge systems
AI-assisted literature review, competitive intelligence and scientific knowledge management can make teams faster when source traceability and human review remain intact.
Commercial AI
Search analysis, content operations, account intelligence and reporting can improve commercial workflows. Patient, HCP and confidential research data demand disciplined governance.
Reference: FDA Artificial Intelligence for Drug Development and the agency's January 2025 draft AI guidance.
Life-science search is often a technical question hiding inside a commercial decision.
A scientist may search a method. A biotech executive may search a CDMO capability. A pathologist may search a biomarker. A physician may search emerging evidence. An investor may ask an AI system to map a competitive field. Search strategy should understand what those queries mean, not simply whether they contain a keyword.
Scientific intent
Mechanism, target, modality, assay, method, biomarker, disease biology, publications and technical comparisons can create early authority before commercial intent is explicit.
Commercial intent
CDMO capabilities, CRO services, API synthesis, instruments, diagnostics, platforms, partnerships, demos and enterprise solutions can map directly to business-development demand.
AI answer visibility
Clear entities, pipeline relationships, regulatory status, mechanisms, evidence and source-backed explanations help answer engines distinguish what a company actually does from generic biotech language.
Sometimes the total addressable market is not millions of people. It is 75 companies and 300 people who matter.
Account-based marketing
CDMOs, CROs, tools, instruments and enterprise platforms often benefit from identifying target accounts and building useful technical journeys around them rather than chasing broad lead volume.
Paid search
Specific capability and problem queries can have high commercial intent. Landing pages need enough technical proof to justify the click.
LinkedIn / professional media
Role, company, therapeutic area and account context can support B2B reach, but the creative still has to be interesting enough for a scientist or executive to care.
Congress campaigns
Pre-meeting targeting, appointment generation, booth support, live content, retargeting and follow-up can turn an expensive conference into more than a badge collection.
For patient-facing pharmaceutical or trial campaigns, the media strategy has to reflect applicable platform policies, privacy and promotional rules. For enterprise life science, the bigger problem is often the opposite: the audience is so narrow that precision matters more than reach.
The website should let a scientist go deep without making the CEO drown on the way in.
Multi-level explanation
Start with the commercial significance, then let technical visitors descend into mechanism, data, publications, posters, methods and supporting evidence. Depth should be available, not forced into every paragraph.
Pipeline clarity
Assets, targets, indications, phases, partnerships and program status should remain consistent across corporate pages, investor materials and scientific content.
Publication & congress libraries
Posters, abstracts, manuscripts, presentations and scientific resources should be searchable, dated and connected to the relevant program or technology.
Regulatory-status clarity
Investigational programs should look investigational. Approved products should link to appropriate labeling and safety information. Device status should use accurate clearance, approval or authorization language.
Business-development paths
Partnering, licensing, CRO/CDMO inquiries, demos and technical conversations should have clear paths distinct from patient or media contact.
CMS flexibility
WordPress can work very well for many scientific organizations; larger regulated enterprises may use other content platforms. I care more about governance, speed, structure, maintainability and search than forcing every company into one stack.
Explore integrated digital strategy, websites, search and paid media →
Life-science reputation is built before the press release and tested after it.
Scientific reputation comes from data quality, investigators, publications, congresses, partnerships, leadership credibility, manufacturing execution and whether past claims age well. PR can amplify those things. It cannot create them.
Investor communication introduces another audience that wants the science translated into milestone, differentiation, risk, market size, competitive context and capital requirements. The best explanation respects both sides: investors should not need a molecular biology degree, and scientists should not cringe when they read the corporate description.
Recruiting is part of reputation too. Highly specialized scientists, regulatory leaders, clinicians, engineers and operators evaluate whether the company appears rigorous, funded, purposeful and capable of doing the work it claims to do.
Approved, cleared, authorized, investigational and “FDA registered” describe different things.
Life-science communication becomes much safer when the team treats regulatory vocabulary as technical vocabulary.
Prescription drug promotion
FDA OPDP reviews prescription-drug promotion for false or misleading communication and emphasizes truthful, balanced, accurate presentation. Benefit claims and risk information cannot be separated by enthusiasm.
Investigational products
An IND, clinical trial or promising dataset does not make a product FDA approved. Corporate and trial communication should not present safety or efficacy as established before it is.
Medical devices
510(k) clearance, De Novo classification and PMA approval are different pathways. The exact regulatory status should be used rather than the catch-all phrase “FDA approved.”
Biologics & gene therapy
Licensed products, investigational therapies, vectors, cells and gene-editing platforms have product-specific statuses. One approved therapy does not validate every technology in the modality.
Preclinical evidence
Cell, animal and model-system evidence can support mechanism and development rationale. It should not be rewritten as a human clinical outcome.
Scientific uncertainty
Limitations, confidence intervals, subgroup context, surrogate endpoints and competing interpretations are not enemies of marketing. They are how sophisticated audiences decide whether the claim deserves trust.
References: FDA OPDP regulatory information and FDA medical-device premarket pathways.
The KPI changes when the company is trying to license an asset instead of sell a subscription.
| Metric | What it can tell me | What it cannot tell me alone |
|---|---|---|
| Qualified scientific / commercial inquiries | Whether the right organizations and technical buyers are discovering the company. | Deal quality, scientific fit or probability of close. |
| Target-account engagement | Whether priority partners, sponsors, labs or enterprise buyers are consuming relevant content. | Internal buying dynamics or strategic priority. |
| Partnering conversations | Whether positioning is creating licensing, co-development or alliance opportunities. | Economics, diligence outcome or scientific compatibility. |
| Clinical-trial funnel | Where awareness, screening and enrollment communication may be limiting recruitment. | Protocol feasibility or clinical eligibility. |
| HCP / institutional adoption | Whether education and commercial work are moving relevant decision-makers toward use. | Clinical appropriateness for an individual patient. |
| Organic scientific visibility | Whether technical content is earning discovery around mechanisms, methods, capabilities and questions. | Commercial value without attribution and qualification. |
| Share of relevant conversation | Whether media, congress, scientific and AI-search visibility is increasing around the right concepts. | Whether the science itself has become more valuable. |
Life sciences clusters matter because science, capital, talent, hospitals and infrastructure cluster too.
I use geography where it explains ecosystem behavior, not as a list of cities inserted for search engines.
Boston / Cambridge & the Northeast corridor
Dense biotech, academic medicine, venture capital, pharma, CRO/CDMO relationships and specialized talent make the Boston/Cambridge ecosystem qualitatively different from a dispersed market. New York/New Jersey and Philadelphia add major pharma, health systems, finance and manufacturing connections.
Bay Area, San Diego & Southern California
Biotechnology, computational science, devices, diagnostics and venture ecosystems create strong cross-pollination between software, engineering and biology. Los Angeles adds large clinical, academic, media and consumer-health dimensions.
Research Triangle, Nashville & emerging hubs
North Carolina brings research, biomanufacturing and clinical-development depth. Nashville adds healthcare-enterprise and executive infrastructure. Other clusters can be attractive because specialized talent, facilities or operating costs create advantages outside the largest coastal markets.
Florida & Central Florida
Florida connects growing healthcare markets, universities, research organizations, aerospace/engineering crossover, clinical populations and international access. From DeLand and Greater Orlando, I can use local context without pretending every biotech company should market itself as a Florida company.
Miami & international health markets
Miami combines international capital, Latin American connections, healthcare, university activity and a growing technology ecosystem. That can matter for investors, medical travel, partnerships and cross-border visibility.
The science travels
Biotech and pharma buyers are often national or global. A laboratory, manufacturing site or clinical center may be local; the partnership, investor or technical buyer may be thousands of miles away. Market design should follow the decision network.
Bring me the molecule, platform, device, assay or scientific problem before somebody turns it into a generic marketing brief.
Maybe the science team thinks the website is superficial. Maybe the CEO thinks the science team has written a website only twelve people can understand. Maybe the laboratory has exceptional capability and weak commercial visibility. Maybe the biotech needs partnering conversations. Maybe the CDMO needs the right ten programs, not ten thousand form fills. Maybe a device and therapy have to be explained together. Maybe the company is doing frontier science and every agency proposal begins by asking what color the brand should be.
I work with founders, scientists, physicians, executives, marketing leaders, business-development teams, investors and technical operators. Sometimes I am the outside strategist. Sometimes I work more like a fractional CMO. Sometimes I take direct responsibility for positioning, search, AI visibility, content, websites, paid media, account strategy, analytics or implementation.
This is the kind of work I enjoy most because the marketing cannot be separated from learning the system. I need enough understanding of the mechanism, evidence, buyer and operating reality to ask better questions. The goal is not to impersonate the scientist. It is to make the scientist's work commercially legible.
Pharmaceutical, biotechnology & life sciences marketing FAQs
The questions get technical quickly. That is a feature of the market, not something the marketing needs to hide.
What does a life sciences marketing consultant do?
I help pharmaceutical, biotechnology and life-science organizations connect scientific positioning, commercial strategy, technical communication, SEO, AI search, websites, account-based marketing, paid media, partnerships, reputation and measurement to the actual stage and business model of the company.
Do you work with pharmaceutical companies?
Yes. Pharmaceutical strategy can include corporate positioning, therapeutic-area education, HCP and patient communication, launch support, digital strategy, SEO, paid media, websites, market-access communication and lifecycle visibility, with promotional claims reviewed against applicable FDA requirements.
Do you work with biotechnology companies?
Yes. I work with biotech and platform-company narratives that may involve therapeutics, synthetic biology, genomics, gene editing, cell therapy, computational biology, diagnostics, research tools or other complex technologies. The commercial story needs to reflect both the scientific evidence and the business model.
Can you help CRISPR and gene-editing companies?
Yes. I can help explain CRISPR/Cas systems, ex vivo editing, base editing, prime editing, delivery, targeting and related concepts at the level appropriate to investors, partners, scientists, clinicians or broader audiences. The copy should clearly distinguish approved products from investigational programs and research-stage technologies.
Is CRISPR actually used in an FDA-approved therapy?
Yes. CASGEVY is an FDA-approved autologous cellular therapy in which a patient's hematopoietic stem cells are edited using CRISPR/Cas9. FDA expanded the labeled population in 2026 to certain patients aged 2 years and older with sickle-cell disease or transfusion-dependent beta-thalassemia.
Can you help cell and gene therapy companies?
Yes. Strategy can address autologous and allogeneic cell therapy, CAR-T and other engineered immune cells, viral-vector gene therapy, ex vivo gene editing, rare-disease ecosystems, manufacturing, treatment-center adoption, referral pathways and scientifically accurate market education.
Can you help companies working on base editing or prime editing?
Yes. These technologies can be explained in relation to classic nuclease-based editing while keeping development status explicit. I would focus on the actual program's targeting, delivery, editing characteristics, evidence and potential therapeutic relevance rather than borrowing credibility from unrelated approved gene-editing products.
Do you work with RNA therapeutics?
Yes. RNA-related work can include mRNA, siRNA, antisense oligonucleotides and other approaches. The communication should explain what the molecule is intended to do, how it is delivered, what evidence exists and why the modality fits the biological problem.
Can you help antibody, ADC, bispecific and radiopharmaceutical companies?
Yes. I can work with the scientific and commercial narrative around antibodies, antibody-drug conjugates, multispecific platforms, targeted radiopharmaceuticals and other advanced therapeutic modalities, including mechanism, differentiation, clinical evidence, administration and adoption.
How does laboratory marketing connect to biotech and pharma?
Laboratories are central to life sciences. Drug discovery uses assays; clinical development uses bioanalytics, pathology, sequencing, biomarkers and central labs; manufacturing depends on QC and release testing; precision medicine often depends on diagnostics. Paper Boat Media's Laboratory Marketing Agency work provides a natural bridge between scientific measurement and life-science commercialization.
Can you market clinical and diagnostic laboratories too?
Yes. Paper Boat Media has specialized laboratory marketing work covering clinical and diagnostic labs, analytical testing, molecular diagnostics, pathology, research labs, instruments, automation, LIMS, LIS, ELN and scientific software. Laboratory buyers and life-science buyers overlap often, but the commercial journeys are not identical.
Do you work with medical-device companies?
Yes, especially where devices intersect with therapeutics, diagnostics, drug delivery, surgery, clinical software, imaging or combination products. Device-led markets have their own regulatory pathways, procurement systems, reimbursement questions and technical adoption patterns, so I keep those distinctions visible.
What is the difference between FDA cleared and FDA approved for medical devices?
They are not interchangeable. Many devices reach market through 510(k) clearance based on substantial equivalence to a predicate. Novel low-to-moderate-risk devices without a predicate may use the De Novo pathway, while Class III high-risk devices generally require Premarket Approval. Marketing should use the product's actual regulatory status.
Can you help companion-diagnostic companies?
Yes. Companion diagnostics connect laboratory testing, biomarker strategy and therapeutic adoption. Strategy may need to reach laboratories, pathologists, oncologists, health systems, payers and patients while making test availability, specimen workflow and the relationship to the therapy understandable.
Can you help molecular-diagnostic and liquid-biopsy companies?
Yes. I can help communicate intended use, analyte, methodology, analytical and clinical evidence, workflow, specimen requirements, target users and business value without reducing a sophisticated diagnostic to a vague 'simple blood test' claim.
Do you work with CDMOs and CMOs?
Yes. CDMO and CMO growth can involve technical positioning, capabilities, scale-up, tech transfer, quality, manufacturing platforms, fill-finish, capacity, facility proof, account-based marketing, SEO, trade shows, business-development content and conversion paths for sponsor inquiries.
Can you help API manufacturers and specialty-chemistry companies?
Yes. API and specialty-chemistry strategy can focus on process capability, route development, scale, impurity control, analytical support, containment, quality systems, supply reliability and the applications or program stages the manufacturer is equipped to support.
Do you work with CROs and clinical-research service companies?
Yes. CRO marketing can address therapeutic expertise, trial operations, biostatistics, regulatory services, site networks, data, patient recruitment, laboratory services and sponsor confidence. The best positioning explains where the organization is especially strong rather than relying on generic 'end-to-end' language.
Can you help with clinical-trial recruitment?
Yes, from the communication and marketing side. That can include trial finders, patient-friendly study information, digital awareness, site and investigator outreach, referral education and advocacy relationships. Eligibility, informed consent, protocol design and clinical conduct remain with qualified sponsor, site, IRB and clinical teams.
Can you market an investigational drug as promising?
The exact language should be reviewed in context. Investigational products should not be promoted as proven safe or effective before approval. Corporate and scientific communications can accurately describe mechanism, development stage and study data while making limitations and regulatory status clear.
Can you help medical affairs teams?
Yes. I can support scientific content systems, congress amplification, publication visibility, evidence communication, disease-state education and digital organization while respecting the distinction between scientific exchange and commercial promotion.
Can you help with scientific congress and conference strategy?
Yes. Strategy can include pre-event targeting, meeting pages, appointment generation, posters and publication organization, live content, expert interviews, paid amplification, retargeting and post-meeting follow-up. The communication should reflect the status and limitations of the data presented.
Can you help with market access and payer communication?
Yes, from the strategic communication side. Market-access narratives may need to explain clinical value, population, treatment pathway, administration, site of care, diagnostic requirements and economic context for payers, formulary teams or health systems. Formal HEOR and regulatory submissions require appropriately qualified specialists.
Can you help rare-disease companies?
Yes. Rare-disease commercialization often depends on specialist mapping, diagnostic pathways, genetic testing, advocacy organizations, centers of excellence, referral education and family communication. Small patient populations can require more precision, not less.
Can you help life-science companies with AI?
Yes. AI can support discovery, literature and data workflows, clinical development, manufacturing, regulatory analysis, commercial intelligence and marketing. When AI contributes to information used for regulatory decision-making, model credibility and context of use become materially different from ordinary business automation.
Does FDA have guidance on AI in drug development?
FDA issued draft guidance in January 2025 describing a risk-based credibility assessment framework for AI models used to generate information or data supporting regulatory decisions about drug and biological product safety, effectiveness or quality. The agency also maintains an active AI-for-drug-development program.
Can you provide SEO for biotech and life-science companies?
Yes. Life-science SEO can cover technical mechanisms, disease biology, platforms, methods, assays, publications, manufacturing capabilities, diagnostics, clinical questions, corporate entities and commercial services. Search strategy should match scientific intent rather than simply repeat high-volume industry terms.
Can you help life-science companies appear in AI search?
Yes. GEO, AEO and AI Search Optimization are particularly useful in technical markets because answer systems need clear entities, mechanisms, pipeline relationships, evidence, regulatory status and source-backed explanations before they can represent the company accurately.
Can you run account-based marketing for life-science companies?
Yes. ABM can be valuable for CDMOs, CROs, laboratory technology, instruments, software, platform companies and other B2B life-science organizations whose real buyer universe may be a small number of high-value accounts.
Can you manage PPC for biotech, pharma or laboratory companies?
Yes, when paid search or professional media fits the commercial goal and applicable promotional rules. I care about qualified scientific or commercial actions—partner inquiries, sponsor conversations, demos, accounts, HCP engagement or appropriate patient actions—rather than inexpensive clicks.
Can you redesign a biotech or life-sciences website?
Yes. I can work on website strategy, WordPress where appropriate, information design, pipeline presentation, scientific resources, publication libraries, business-development pathways, technical SEO, AI discovery, accessibility and performance. Larger regulated companies may use other enterprise content-management systems.
Can you help a biotech company communicate with investors?
Yes. I can help translate technical differentiation, pipeline logic, milestones, competitive context and business strategy into clearer investor and stakeholder communication. Securities-law compliance, financial disclosures and material-information decisions remain with the company's legal, finance and investor-relations professionals.
Can you help life-science companies recruit scientists and technical leaders?
Yes. Employer reputation, careers content, scientific leadership, mission, facilities, research quality, location and company credibility all influence specialized recruiting. Talent strategy becomes particularly important when growth is constrained by hard-to-find scientific or operational expertise.
Do you work with frontier science beyond conventional biotech?
Yes. Paper Boat Media's frontier-science work extends into synthetic biology, advanced bioengineering, neurotechnology, biomimetics, scientific instrumentation, AI, robotics and other deep technologies where the market needs a technically literate commercialization narrative.
Do you only work with life-science companies in Florida?
No. Paper Boat Media is based in DeLand, Florida, and I understand Florida and Central Florida healthcare and technology markets particularly well, but life-science work is national and can be international. Geography matters when it changes talent, capital, clinical networks, manufacturing, partnerships or market access.
Can you work as a consultant, fractional CMO or hands-on marketing partner?
Yes. Engagements can range from focused positioning or search projects to retained advisory, fractional CMO leadership and hands-on execution. I can work with internal scientists and marketing teams, coordinate specialized vendors or directly own selected parts of the growth system.
What should a life-science company bring to an initial conversation?
Bring the product or platform story, current stage, major evidence, target audiences, commercial objective and the problems that feel unresolved. A polished marketing brief is not required. I would rather understand what the science and business are actually trying to accomplish.
Do you work across different therapeutic areas?
Yes. Strategy can be adapted to oncology, rare and genetic disease, immunology, neuroscience, metabolic disease, cardiovascular and renal medicine, infectious disease and vaccines, ophthalmology, respiratory disease, dermatology, reproductive health and other therapeutic areas. The referral network, evidence, patient-finding problem and adoption pathway change by disease.
Can you help oncology and precision-medicine companies?
Yes. Oncology strategy may need to connect therapy, biomarker testing, companion diagnostics, pathologists, oncologists, treatment centers, infusion or procedural workflows, publications and patient identification. The commercialization system can be inseparable from the diagnostic system.
Can you help vaccine and infectious-disease companies?
Yes. Vaccine and infectious-disease communication can involve HCPs, public health, procurement, distribution, surveillance, seasonality, patient education and misinformation. Claims should remain tightly grounded in current labeling and evidence.
Can you help life-science research-tool and instrument companies?
Yes. Research tools may include sequencing, single-cell and spatial platforms, flow cytometry, mass spectrometry, chromatography, laboratory automation, reagents, organoids, bioprocessing systems, LIMS, ELN and scientific data platforms. Technical buyers usually respond to application proof and workflow relevance more than generic brand language.
Can you market laboratory automation and scientific software?
Yes. Laboratory automation, robotics, LIMS, ELN, scientific software and data platforms can be marketed through technical SEO, AI search, application content, demos, account-based marketing, trade shows and enterprise sales support. The strategy should speak to scientists as well as IT, quality, operations and procurement when those roles matter.
If it takes twenty minutes to explain, that is probably where I become useful.
Maybe the platform is elegant and the corporate story is not. Maybe the laboratory is technically excellent and commercially invisible. Maybe a clinical-stage company needs a cleaner narrative before the next milestone. Maybe a CDMO needs better accounts. Maybe a device, diagnostic and therapy have to be explained together. Maybe the frontier-science team is tired of hearing that the solution is to “simplify the science.”
I do not need the science to become simple. I need to understand it well enough to help the right audience understand why it matters.